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Summary
 
Three novel streptococcal superantigen genes (
 
spe-g
 
, 
 
spe-h
 
, and 
 
spe-j
 
) were identified from the
 
Streptococcus pyogenes
 
 M1 genomic database at the University of Oklahoma. A fourth novel gene
(
 
smez-2
 
) was isolated from the 
 
S. pyogenes
 
 strain 2035, based on sequence homology to the
streptococcal mitogenic exotoxin z (
 
smez
 
) gene. SMEZ-2, SPE-G, and SPE-J are most closely
related to SMEZ and streptococcal pyrogenic exotoxin (SPE)-C, whereas SPE-H is most simi-
lar to the staphylococcal toxins than to any other streptococcal toxin. Recombinant (r)SMEZ,
rSMEZ-2, rSPE-G, and rSPE-H were mitogenic for human peripheral blood lymphocytes
with half-maximal responses between 0.02 and 50 pg/ml (rSMEZ-2 and rSPE-H, respectively).
SMEZ-2 is the most potent superantigen (SAg) discovered thus far. All toxins, except rSPE-G,
were active on murine T cells, but with reduced potency. Binding to a human B-lymphoblas-
toid line was shown to be zinc dependent with high binding affinity of 15–65 nM. Evidence
from modeled protein structures and competitive binding experiments suggest that high affinity
binding of each toxin is to the major histocompatibility complex class II 
 
b
 
 chain. Competition
for binding between toxins was varied and revealed overlapping but discrete binding to subsets
of class II molecules in the hierarchical order (SMEZ, SPE-C) 
 
. 
 
SMEZ-2 
 
. 
 
SPE-H 
 
. 
 
SPE-G.
The most common targets for the novel SAgs were human V
 
b
 
2.1- and V
 
b
 
4-expressing T
cells. This might reflect a specific role for this subset of V
 
b
 
s in the immune defense of gram-
positive bacteria.
Key words: superantigen • major histocompatibility complex class II • T cell receptor • 
streptococcal exotoxin • zinc dependency
 
S
 
treptococcus pyogenes
 
 is a gram-positive pathogenic bacte-
rium that produces a number of distinct but partially re-
lated streptococcal pyrogenic exotoxins (SPEs).
 
1
 
 These tox-
ins belong to a bigger family of T cell mitogens or
superantigens (SAgs), also found in viruses and other bacte-
ria, but primarily in 
 
Staphylococcus aureus
 
 (1–6). SAgs simul-
taneously bind to MHC class II antigens and TCR mole-
cules and stimulate a large number of T cells, which leads
to high systemic levels of the cytokines TNF-
 
a
 
 and IL-1
 
b
 
and of T cell mediators like IL-2 and IFN-
 
g
 
 (1, 7–9). The
resulting pathological conditions include fever and shock
(10–11).
SPE-A (12), SPE-C (13), and streptococcal SAg (SSA;
reference 14) are significantly related to each other and to the
 
S. aureus
 
 enterotoxins (SEs), building a homologous pro-
tein family with sequence identities from 20 to 
 
.
 
90% (15).
Bacterial SAgs are monomeric proteins, expressed as precur-
sor molecules with typical bacterial signal peptides. The se-
creted mature toxins have molecular masses of 24–28 kD (4).
SAgs bind to MHC class II outside the peptide binding
groove and to all TCRs bearing a particular V
 
b
 
 region
(16–19). Crystal structures of SEA (20), SEB (21), SEC2
(22), SED (23), toxic shock syndrome toxin (TSST; refer-
ence 24), and SPE-C (25) show a conserved folding pat-
tern, comprising a NH
 
2
 
-terminal 
 
b
 
-barrel globular domain
and a COOH-terminal globular domain based on a 
 
b
 
-grasp
motif.
All SAgs examined thus far, except SPE-C, have a ge-
neric binding site for the invariant 
 
a
 
 chain of MHC class II
located in the NH
 
2
 
-terminal domain (26–28). There are
two structural models for the 
 
a
 
 chain binding. TSST binds
to the invariant 
 
a
 
1 domain but lies across the top of the
 
1
 
Abbreviations used in this paper:
 
 GST, glutathione-S-transferase; KD, Ka-
wasaki disease; ORF, open reading frame; SAg, superantigen; SCR,
structurally conserved region; SE, staphylococcal enterotoxin; SMEZ,
streptococcal mitogenic exotoxin Z; SPE, streptococcal pyrogenic exo-
toxin; SSA, streptococcal SAg; TSST, toxic shock syndrome toxin. 
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molecule, contacting peptide and preventing continued
TCR contact (26–27). SEB binds out to one side of the 
 
a
 
1
domain 
 
a
 
 chain and does not contact peptide residues (28).
TCR contact is not excluded and indeed, SEB appears to
rely on continued TCR/MHC class II contact for activity.
The unique exception to 
 
a
 
 chain binding is SPE-C, which
has surrendered its MHC class II 
 
a
 
 chain binding site in fa-
vor of a protein dimer interface (25, 29). Some toxins, like
SEA, have in addition to their 
 
a
 
 chain binding a second
high affinity binding site for the polymorphic MHC class II
 
b
 
 chain, mediated by a tetrameric zinc coordination com-
plex between four SEA residues and the highly conserved
His81 of the HLA-DR1 
 
b
 
 chain (20, 30, 31). This bifunc-
tional binding mode enables SEA to cross-link MHC class
II on the surface of APCs (32). SPE-C lacks the generic
MHC class II 
 
a
 
 chain binding site and binds MHC class II
only via the polymorphic 
 
b
 
 chain (29). As shown from the
crystal structure, SPE-C also has a dimerization interface
that might be stabilized by a second zinc binding site (25).
Binding of SPE-C dimers to MHC class II represents an al-
ternative mechanism for class II cross-linking. A third puta-
tive mode for class II cross-linking was suggested for SED
based on the recently published SED crystal structure (23).
Apparently, SED forms zinc-dependent dimers that bind to
the MHC class II 
 
a
 
 chain in a SEB-like mechanism, using
the NH
 
2
 
-terminal low affinity binding site.
SAgs can be identified by their particular V
 
b
 
 profile.
SPE-A preferably stimulates T cells that carry V
 
b
 
12.5 and
V
 
b
 
14 TCRs (33), but stimulation of V
 
b
 
2 and V
 
b
 
15 has
also been reported (34). SPE-C almost exclusively stimu-
lates V
 
b
 
2 TCR (29).
SPE-B, a powerful streptococcal protease, has been
shown to have mitogenic activity for V
 
b
 
8-bearing human
T cells. However, rSPE-B has no SAg activity, suggesting
that the purified SPE-B was contaminated with traces of
other co-purified SAgs. In addition, several reports have also
shown other purified streptococcal proteins to have V
 
b
 
8-
like stimulation activity, later to be confirmed as a result of
a potent contaminating SAg called SPE-X (35). All at-
tempts to purify SPE-X or to identify the 
 
spe-x
 
 gene have
so far been unsuccessful. Toyosaki et al. (36) described a
SAg called mitogenic factor (MF) that activates V
 
b
 
2, V
 
b
 
7,
V
 
b
 
8, and V
 
b
 
18 TCR, but its potency to stimulate T cells
was 100–1,000 times weaker than that of SPE-A and SPE-C.
It is therefore very unlikely that MF is the contaminating
agent of other toxin preparations.
Another recently discovered toxin, the streptococcal
mitogenic exotoxin Z (SMEZ), that displayed homology
to other SAgs, was mitogenic for rabbit T cells (37). The
potency and V
 
b
 
 specificity for human and mouse T cells
was not determined.
To identify other SAgs, the Oklahoma University 
 
S.
pyogenes
 
 genome database (http://www.genome.ou.edu/
strep.html) was screened using small regions of highly con-
served protein sequences on all the streptococcal and staph-
ylococcal SAgs. This screen yielded three complete and
one incomplete open reading frames (ORFs) encoding po-
tential SAgs. Each has been expressed as recombinant pro-
tein and examined for the potency to stimulate human and
murine T cells. Here we describe the immunological and
biochemical characterization of recombinant forms of
SMEZ, SMEZ-2, SPE-G, and SPE-H. Despite high se-
quence homology, striking variation in function was ob-
served. Both SMEZ and SMEZ-2 are probably responsible
for the V
 
b
 
8-stimulating activity referred to as SPE-X.
 
Materials and Methods
 
Identification of Novel SAgs.
 
The novel SAgs were identified
by searching the 
 
S. pyogenes
 
 M1 genome database at the Univer-
sity of Oklahoma with highly conserved 
 
b
 
5 and 
 
a
 
4 regions of
streptococcal and staphylococcal SAgs, using a TBlastN search
program.
The ORFs were defined by translating the DNA sequences
around the matching regions and aligning the protein sequences
to known SAgs using the computer program Gap. Multiple
alignments and dendrograms were performed with Lineup and
Pileup. We used the FASTA program for searching the SwissProt
(Amos Bairoch, Switzerland) and PIR (Protein Identification
Resource) protein databases.
The leader sequences of SPE-G and SPE-H were predicted
using the SP Scan program. All computer programs are part of
the Genetics Computer Group package (version 8).
 
Cloning of smez, smez-2, spe-g, and spe-h.
 
50 ng of 
 
S.
 
 
 
pyogenes
 
M1 (ATCC 700294) or 
 
S.
 
 
 
pyogenes
 
 2035 genomic DNA was
used as a template to amplify the 
 
smez
 
 DNA fragment and the
 
smez-2
 
 DNA fragment, respectively, by PCR using the primers
smez-fw (TGGGATCCTTAGAAGTAGATAATA) and smez-
rev (AAGAATTCTTAGGAGTCAATTTC) and Taq Poly-
merase (Promega Corp.). The primers contain a terminal tag with
the restriction enzyme recognition sequences BamHI and EcoRI,
respectively. The amplified DNA fragment, encoding the mature
protein without the leader sequence (37) was cloned into a T-tailed
pBlueScript SKII vector (Stratagene).
 
Spe-g
 
 and 
 
spe-h
 
 were cloned by a similar approach, using the
primers spe-g-fw (CTGGATCCGATGAAAATTTAAAAGATT-
TAA) and spe-g-rev (AAGAATTCGGGGGGAGAATAG), and
spe-h-fw (TTGGATCCAATTCTTATAATACAACC) and spe-
h-rev  (AAAAGCTTTTAGCTGATTGACAC), respectively.
The DNA sequences of the subcloned toxin genes were con-
firmed by the dideoxy chain termination method using a Licor
automated DNA sequencer (model 4200). As the DNA sequences
from the genomic database are all unedited raw data, three sub-
clones of every cloning experiment were analyzed to insure that
no Taq polymerase–related mutations were introduced. The
DNA sequence of the 
 
smez-2
 
 gene has been annotated in EMBL/
Genbank/DDBJ under accession number AF086626.
 
Expression and Purification of rSMEZ, rSMEZ-2, rSPE-G, and
rSPE-H.
 
Subcloned 
 
smez
 
, 
 
smez-2
 
, and 
 
spe-g
 
 fragments were cut
from pBlueScript SKII vectors, using restriction enzymes BamHI
and EcoRI (GIBCO BRL), and cloned into pGEX-2T expres-
sion vectors (Pharmacia Biotech). Due to an internal EcoRI
restriction site within the 
 
spe-h
 
 gene, the pBlueScript:spe-h sub-
clone was digested with BamHI and HindIII and the 
 
spe-h
 
 frag-
ment was cloned into a modified pGEX-2T vector that contains
a HindIII 3
 
9
 
 cloning site.
rSMEZ, rSMEZ-2, and rSPE-H were expressed in 
 
Escherichia
coli
 
 DH5
 
a
 
 cells as glutathione-S-transferase (GST) fusion pro-
teins. Cultures were grown at 37
 
8
 
C and induced for 3–4 h after 
91
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adding 0.2 mM isopropyl-
 
b
 
-
 
d
 
-thiogalactopyranoside. GST–
SPE-G fusion protein was expressed in cells grown at 28
 
8
 
C.
The GST fusion proteins were purified on glutathione (GSH)
agarose as previously described (29) and the mature toxins were
cleaved off from GST by trypsin digestion. All recombinant tox-
ins, except rSMEZ, were further purified by two rounds of cation
exchange chromatography using carboxy methyl sepharose (Phar-
macia Biotech). The GST-SMEZ fusion protein was trypsin di-
gested on the GSH-column and the flow-through containing the
SMEZ was collected.
 
Gel Electrophoresis.
 
All purified recombinant toxins were
tested on a 12.5% SDS-polyacrylamide gel according to Laemmli’s
procedure. The isoelectric point of the recombinant toxins was
determined by isoelectric focusing on a 5.5% polyacrylamide gel
using ampholine, pH 5–8 (Pharmacia Biotech). The gel was run
for 90 min at 1 Watt constant power.
 
Toxin Proliferation Assay.
 
Human PBLs were purified from
blood of a healthy donor by Histopaque Ficoll (Sigma Chemical
Co.) fractionation. The PBLs were incubated in 96-well round-
bottomed microtiter plates at 10
 
5
 
 cells per well with RPMI-10
(RPMI with 10% FCS) containing varying dilutions of recombi-
nant toxins. The dilution series was performed in 1:5 steps from a
starting concentration of 10 ng/ml of toxin. Pipette tips were
changed after each dilution step. After 3 d, 0.1 
 
m
 
Ci [
 
3
 
H]thymi-
dine was added to each well and cells were incubated for another
24 h. Cells were harvested and counted on a scintillation counter.
Mouse leukocytes were obtained from spleens of five different
mouse strains (SJL, B10.M, B10/J, C3H, and BALB/c). Spleno-
cytes were washed in DMEM-10, counted in 5% acetic acid, and
incubated on microtiter plates at 10
 
5
 
 cells per well with DMEM-
10 and toxins as described for human PBLs.
 
TCR V
 
b
 
 Analysis.
 
V
 
b
 
 enrichment analysis was performed
by anchored multiprimer amplification (38). Human PBLs were
incubated with 20 pg/ml of recombinant toxin at 10
 
6
 
 cells/ml for
3 d. A twofold volume expansion of the culture followed with
medium containing 20 ng/ml IL-2. After another 24 h, stimu-
lated and resting cells were harvested and RNA was prepared us-
ing Trizol reagent (GIBCO BRL). A 500 bp 
 
b
 
 chain DNA probe
was obtained by anchored multiprimer PCR as previously de-
scribed (38), radiolabeled, and hybridized to individual V
 
b
 
s and a
C
 
b
 
 DNA region dot-blotted on a Nylon membrane. The mem-
brane was analyzed on a Storm PhosphorImager using Im-
ageQuant software (Molecular Dynamics). Individual V
 
b
 
s were
expressed as a percentage of all the V
 
b
 
s determined by hybridiza-
tion to the C
 
b
 
 probe.
 
Jurkat Cell Assay.
 
Jurkat cells (a human T cell line) and LG-2
cells (a human B lymphoblastoid cell line, homozygous for HLA-
DR1) were harvested in log phase and resuspended in RPMI-10.
100 
 
m
 
l of the cell suspension, containing 10
 
5
 
 Jurkat cells and 2 
 
3
 
10
 
4
 
 LG-2 cells were mixed with 100 
 
m
 
l of varying dilutions of re-
combinant toxins on 96-well plates. After incubating overnight at
37
 
8
 
C, 100-
 
m
 
l aliquots were transferred onto a fresh plate and 100
 
m
 
l (10
 
4
 
) of SeI cells (IL-2–dependent murine T cell line) per well
were added. After incubating for 24 h, 0.1 
 
mCi [3H]thymidine
was added to each well and cells were incubated for another 24 h.
Cells were harvested and counted on a scintillation counter. As a
control, a dilution series of IL-2 was incubated with SeI cells.
Computer-aided Modelling of Protein Structures. Protein struc-
tures of SMEZ2, SPE-G and SPE-H were created on a Silicon
Graphics computer using InsightII/Homology software (Biosym
Technologies). The SAgs SEA, SEB, and SPE-C were used as
reference proteins to determine structurally conserved regions
(SCRs). Coordinate files for SEA (1ESF), SEB (1SEB), and SPE-C
(1AN8) were downloaded from the Brookhaven Protein Database.
The primary amino acid sequences of the reference proteins and
SMEZ-2, SPE-G, and SPE-H, respectively, were aligned, and co-
ordinates from superimposed SCRs were assigned to the model
proteins. The loop regions between the SCRs were generated by
random choice. MolScript software (39) was used for displaying
the computer-generated images.
Radiolabeling and LG-2 Binding Experiments. Recombinant
toxin was radioiodinated by the chloramine T method as previ-
ously described (29). Labeled toxin was separated from free io-
dine by size exclusion chromatography using Sephadex G25
(Pharmacia Biotech). LG2 cells were used for cell binding exper-
iments, as previously described (29). In brief, cells were har-
vested, resuspended in RPMI-10, mixed at 106 cells/ml with
125I-tracer toxin (1 ng) and 0.0001–10 mg of unlabeled toxin, and
incubated at 378C for 1 h. After washing with ice cold RPMI-1
the pelleted cells were analyzed in a gamma counter.
For zinc binding assays, the toxins were incubated in RPMI-
10 alone, RPMI-10 with 1 mM EDTA, or RPMI-10 with 1 mM
EDTA and 2 mM ZnCl2. Scatchard analysis was performed as de-
scribed elsewhere (40).
For competitive binding studies, 1 ng of 125I-tracer toxin
(rSMEZ, rSMES-2, rSPE-G, rSPE-H, rSEA, rSPE-C, or rTSST)
was incubated with 0.0001–10 mg of unlabeled toxin (rSMEZ,
rSMES-2, rSPE-G, rSPE-H, rSEA, rSEB, rSPE-C, and rTSST)
for 1 h. For SEB inhibition studies, 20 ng of 125I-rSEB was used
as tracer and samples were incubated for 4 h.
Results
Identification and Sequence Analysis of Novel SAgs. The Okla-
homa University S. pyogenes M1 genome database is acces-
sible via the internet and contains a collection of more than
300 DNA sequence contigs derived from a shot gun plas-
mid library of the complete S. pyogenes M1 genome. The
currently available DNA sequences cover z95% of the to-
tal genome. We searched this database with a highly con-
served SAg peptide sequence, using a search program that
screens the DNA database for peptide sequences in all six
possible reading frames. We found 8 significant matches
and predicted the ORFs by aligning translated DNA se-
quences to complete protein sequences of known SAgs.
Five matches gave complete ORFs with significant ho-
mology to streptococcal and staphylococcal SAgs. Three of
these ORFs correlate to SPE-C, SSA, and the recently de-
scribed SMEZ (37), respectively. The remaining two
ORFs could not be correlated to any known protein in the
SwissProt and PIR databases. We named these novel puta-
tive sag genes spe-g and spe-h.
One ORF could not be generated completely due to its
location close to the end of a contig. The DNA sequence
of the missing 59-end is located on another contig, and in-
dividual contigs have yet to be assembled in the database.
However, the available sequence shows an ORF for the
137 COOH-terminal amino acid residues of a putative
novel SAg that could not be found in the existing protein
databases. We named this thus far incomplete gene spe-j. In
two cases, a complete ORF could not be defined due to
several out-of-frame mutations. Although DNA sequenc-
ing errors on the unedited DNA sequences cannot be ruled92 Novel Streptococcal Superantigens
out completely, the high frequency of inserts and deletions
probably represent natural mutation events on pseudo-
genes, which are no longer used.
To produce recombinant proteins of SMEZ, SPE-G,
and SPE-H, individual genes (coding for the mature toxins
without leader sequence) were amplified by PCR and sub-
cloned for DNA sequencing. Both S. pyogenes M1 and S.
pyogenes 2035 genomic DNA were used and individual
toxin gene sequences were compared between the two
strains. The spe-h gene was isolated from the M1 strain but
could not be amplified from strain 2035 genomic DNA,
suggesting a restricted strain specificity for this toxin. The
spe-g gene was cloned from both M1 and 2035, and DNA
sequence analysis of both genes showed no differences. The
full-length smez gene was isolated from both strains, but
DNA sequence comparison revealed some striking differ-
ences. The smez gene of strain 2035 showed nucleotide
changes in 36 positions (or 5%) compared with smez from
strain M1 (Fig. 1). The deduced protein sequences differed
in 17 amino acid residues (or 8.1%). This difference was
sufficient to indicate a new gene. We named this gene
smez-2, because it is 95% homologous to smez.
The most significant difference between SMEZ and
SMEZ-2 is an exchanged pentapeptide sequence at posi-
tion 96–100, where the EEPMS sequence of SMEZ is con-
verted to KTSIL in SMEZ-2 (Fig. 1). A second cluster is at
position 111–112, where an RR dipeptide is exchanged for
GK in SMEZ-2. The remaining 10 different residues are
spread over almost the entire primary sequence.
Figure 1. Multiple alignment of SAg protein sequences. The protein
sequences of mature toxins were aligned using the PileUp program on the
GCG package. Regions of high sequence identity are in black boxes. The
boxes below the sequences indicate the structural elements of SPE-C, as
determined from the crystal structure (25). Regions with highest homol-
ogy correspond to the b4, b5, a4, and a5 regions in SPE-C. The clear
box near the COOH terminus represents a primary zinc binding motif, a
common feature of all toxins shown here. The arrows on top of the se-
quence alignment show the regions of sequence diversity between SMEZ
and SMEZ-2. The NH2-terminal part of SPE-J is missing, as the corre-
sponding DNA sequence is not yet available in the database.
Figure 2. SAg family tree. The family tree was created using the
PileUp program on the GCG package and is based on primary amino acid
sequence homology. The SAg family can be divided into three groups (or
subfamilies) and two individual branches (SPE-H and TSST). SMEZ,
SMEZ-2, SPE-G, and SPE-J build a subfamily together with SPE-C. The
complete DNA sequence of the spe-j gene is not yet available, so only
the 135 COOH-terminal amino acid residues of SPE-J could be used for
the alignment.93 Proft et al.
A revised SAg family tree, based on primary amino acid
sequence homology (Fig. 2) now shows three general sub-
families: group A comprises SPE-C, SPE-J, SPE-G, SMEZ,
and SMEZ-2; group B comprises SEC1-3, SEB, SSA,
SPE-A, and SEG; and group C comprises SEA, SEE, SED,
SEH, and SEI. Two SAgs, TSST and SPE-H, do not be-
long to any one of those subfamilies.
SMEZ, SMEZ-2, SPE-G, and SPE-J are most closely re-
lated to SPE-C, increasing the number of this subfamily
from two to five members. SPE-G shows the highest pro-
tein sequence homology with SPE-C (38.4% identity and
46.6% similarity). The homology of SPE-J to SPE-C is
even more significant (56% identity and 62% similarity),
but this comparison is only preliminary due to the missing
NH2-terminal sequence. SMEZ shows 30.9/40.7% homol-
ogy to SPE-C, and SMEZ-2 is 92/93% homologous to
SMEZ. SPE-H builds a new branch in the family tree and
is most closely related to SED, showing 25% identity and
37.3% similarity.
Multiple alignment of SAg protein sequences (Fig. 1)
shows that similarities are clustered within structure-deter-
mining regions, represented by a4, a5, b4, and b5 regions.
This applies to all toxins of the SAg family (data not
shown) and explains why SAgs like SPE-C and SEA have
very similar overall structures despite their rather low se-
quence identity of 24.4%.
Although SPE-H is less related to SPE-C, it shows two
common features with the “SPE-C subfamily”: (i) a trun-
cated NH2-terminus, lacking the a1 region and (ii) a pri-
mary zinc binding motif (H-X-D) at the COOH terminus
(Fig. 1). It has been shown for several SAgs that this motif
is involved in a zinc-coordinated binding to the b chain of
HLA-DR1 (18, 23).
Fusion proteins of GST-SMEZ, GST-SMEZ-2, and
GST-SPE-H were completely soluble and gave yields of
z30 mg/liter. The GST-SPE-G fusion was insoluble when
grown at 378C, but mostly soluble when expressed in cells
growing at 288C. Although soluble GST-SPE-G yields
were 20–30 mg/per liter, solubility decreased after cleavage
of the fusion protein with trypsin. Soluble rSPE-G was
achieved by diluting the GST-SPE-G to ,0.2 mg/ml be-
fore cleavage. After cation exchange chromatography, pu-
rified rSPE-G could be stored at z0.4 mg/ml.
rSMEZ could not be separated from GST by ion ex-
change chromatography. Isoelectric focusing revealed that
the isoelectric points of the two proteins are too similar to
allow separation (data not shown). Therefore, rSMEZ was
released from GST by cleaving with trypsin while still
bound to the GSH agarose column. rSMEZ was collected
with the flow through.
The purified recombinant toxins were applied to SDS-
PAGE and isoelectric focusing (Fig. 3). Each toxin ran as a
single band on the SDS PAA gel, confirming their purity
and their calculated molecular weights of 24.33 (SMEZ),
24.15 (SMEZ-2), 24.63 (SPE-G), and 23.63 (SPE-H) (Fig.
3 A). The isoelectric focusing gel (Fig. 3 B) shows a signifi-
cant difference between rSMEZ and rSMEZ-2. Like most
other staphylococcal and streptococcal toxins, rSMEZ-2
possesses a slightly basic isoelectric point at pH 7–8, but
rSMEZ is acidic with an isoelectric point at pH 6–6.5.
T Cell Proliferation and Vb Specificity. To ensure the na-
tive conformation of the purified recombinant toxins, a
standard [3H]thymidine incorporation assay was performed
to test for their potency to stimulate PBLs. All toxins were
active on human T cells (Fig. 4). rSEA, rSEB, rSPE-C, and
rTSST were included as reference proteins. The mitogenic
potency of these toxins was lower than previously de-
scribed, but is regarded as a more accurate figure. In previ-
ous studies performed by us (29), a higher starting concen-
tration of toxin (100 ng/ml) was used and tips were not
Figure 3. Gel electrophoresis of the purified recombinant toxins. (A)
Two micrograms of purified recombinant toxin were run on a 12.5%
SDS-polyacrylamide gel to show the purity of the preparations. (B) 2 mg
of purified recombinant toxin were run on an isoelectric focusing gel
(5.5% PAA, pH 5–8). The isoelectric point of rSMEZ-2, rSPE-G, and
rSPE-H is similar and was estimated at pH 7–8. The IEP of rSMEZ was
estimated at pH 6–6.5.
Figure 4. Stimulation of human T cells with recombinant toxins. PBLs
were isolated from human blood samples and incubated with varying
concentrations of recombinant toxin. After 3 d, 0.1 mCi [3H]thymidine
was added and cells were incubated for another 24 h, before being har-
vested and counted on a gamma counter. s, unstimulated; m, rSMEZ;
h, rSMEZ-2; r, rSPE-G; i, rSPE-H.94 Novel Streptococcal Superantigens
changed in between dilutions. This led to significant carry-
over across the whole dilution range. In this study, the
starting concentration was 10 ng/ml and tips were changed
in between dilutions, thereby preventing any carry-over.
The half-maximal responses (P50 values) for rSPE-G and
rSPE-H were 2 and 50 pg/ml, respectively. No activity
was detected at ,0.02 pg/ml and 0.1 pg/ml, respectively.
Both toxins are therefore less potent than rSPE-C. rSMEZ
was similar in potency to rSPE-C, with a P50 value of 0.08
pg/ml and no detectable proliferation at ,0.5 fg/ml.
rSMEZ-2 showed the strongest mitogenic potency of all
toxins tested or, as far as we are aware, described elsewhere.
The P50 value was determined at 0.02 pg/ml and rSMEZ-2
was still active at ,0.1 fg/ml. All P50 values are summa-
rized in Table I.
Murine T cells from five different mouse strains were
tested for their mitogenic response to rSMEZ, rSMEZ-2,
rSPE-G, and rSPE-H (Table I). rSPE-G showed no activity
against any of the mouse strains tested. rSPE-H, rSMEZ,
and rSMEZ-2 showed varied potency depending on the in-
dividual mouse strain. For example, rSMEZ-2 was 500-fold
more potent than rSPE-H in the B10/J strain, whereas
rSPE-H was 7.5-fold more active than rSMEZ-2 in the SJL
strain.
The most consistently potent toxin on murine T cells
was rSMEZ-2, with P50 values of 10 pg/ml in B10/J and
800 pg/ml in C3H. rSMEZ varied between 80 pg/ml in
SJL and B10.M and 9,000 pg/ml in C3H. The P50 value
for rSPE-H was between 15 pg/ml in SJL and 5,000 pg/ml
in B10/J.
The human TCR Vb specificity of the recombinant
toxins was determined by multiprimer anchored PCR and
dot-blot analysis using a panel of 17 human Vb DNA re-
gions. The Vb enrichment after stimulation with toxin was
compared with the Vb profile of unstimulated PBLs (Table
II). The sum total of all Vbs stimulated by rSMEZ, rS-
MEZ-2, and rSPE-G was close to 100%, suggesting that
the Vbs used in the panel represent all the targeted Vbs.
On the other hand, the total of the Vbs stimulated by
rSPE-H was only 75%. It is therefore likely that rSPE-H
also stimulated some less common Vbs, which are not rep-
resented in the panel. The most dramatic response was seen
with all toxins, except rSMEZ-2, on Vb2.1 bearing T cells
(21-fold for rSMEZ, 45-fold for rSPE-G, and 22-fold for
rSPE-H). In contrast, rSMEZ-2 gave only a 2.5-fold in-
crease of Vb2.1 T cells. SPE-G also targeted Vb4.1,
Vb6.9, Vb9.1, and Vb12.3 (three- to fourfold). A moder-
Table I. Potency of Recombinant Toxins on Human and Mouse T Cells
Proliferation potential P50 [pg/ml]
Toxin Human SJL B10.M B10/J C3H BALB/c
SEA 0.1 20 12 1.8 19 1,000
SEE 0.2 10 12 1.5 50 15
SEB 0.8 7,000 80,000 5,000 10,000 1,000
TSST 0.2 20 1,000 1.2 100 10
SPE-C 0.1 .100,000 .100,000 .100,000 .100,000 .100,000
SMEZ 0.08 80 80 100 9,000 200
SMEZ-2 0.02 100 15 10 800 18
SPE-G 2 .100,000 .100,000 .100,000 .100,000 .100,000
SPE-H 50 15 800 5,000 100 1,000
Human PBLs and mouse T cells were stimulated with varying amounts of recombinant toxin. The P50 value reflects the concentration of recombi-
nant toxin required to induce 50% maximal cell proliferaton. No proliferation was detected for rSPE-C and rSPE-G at any concentration tested on 
murine T cells.
Figure 5.  Jurkat cell assay. Jurkat cells (bearing a Vb8 TCR) and LG-2
cells were mixed with varying concentrations of recombinant toxin and
incubated for 24 h, before SeI cells were added. After 1 d, 0.1 mCi
[3H]thymidine was added and cells were counted after another 24 h. The
Vb8 targeting SEE was used as a positive control. The negative control
was SEA. Both SMEZ and SMEZ-2 were potent stimulators of Jurkat
cells, indicating their ability to specifically target Vb8-bearing T cells. s,
unstimulated; m, rSEA; h, rSEE; r, rSMEZ; j, rSMEZ-2.95 Proft et al.
Figure 6. Computer generated models of protein structures. The models were
created on a Silicon Graphic computer using InsightII/Homology software. SEA,
SEB, and SPE-C were used as reference proteins to determine structurally con-
served regions. The loop regions were generated by random choice. MolScript
software (39) was used for displaying the computer generated images. (a) All
models show a potential zinc binding site within the b-grasp motif of the toxin
structure. Two zinc binding residues are provided by a primary zinc motif (H-
X-D) and the third ligand (H or D) comes from either the b9 or b10 strand. The
amino acid residues of the b1-b2 loop that corresponds to the HLA-DRI a
chain binding site in SEA and SEB are shown on the right side of the models. In
all three protein models, this loop region is less hydrophobic than in SEA and
SEB, suggesting the lack of the a chain binding site. A, Crystal structures of SPE-C
(25); B, SMEZ-2; C, SPE-G; D, SPE-H. (b) SMEZ-2 model, showing the pre-
dicted location of the 17 residues that are different between SMEZ and SMEZ-2.
The first residue is from SMEZ-2, followed by the position on the primary pro-
tein sequence and the corresponding residue on SMEZ.96 Novel Streptococcal Superantigens
ate enrichment of Vb12.6, Vb9.1, and Vb23.1 (four- to
eightfold) was observed with rSPE-H. Both rSMEZ and
rSMEZ-2 targeted Vb4.1 and Vb8.1 with similiar effi-
ciency (three- to sevenfold). This finding is of particular in-
terest, because Vb8.1 activity had been found in some, but
not all, S. pyogenes culture supernatants and in crude prepa-
rations of SPE-A and SPE-C. Moreover, SPE-B has often
been claimed to have Vb8 specific activity, but has since
been shown to be a contaminant previously called SPE-X
(35). The ability of rSMEZ and rSMEZ-2 to stimulate the
Vb8.1 Jurkat cell line was tested (Fig. 5). rSMEZ was less
potent than the control toxin (rSEE), showing a half-maxi-
mal response of 0.2 ng/ml, compared with 0.08 ng/ml
with rSEE, but rSMEZ-2 was more potent than rSEE (0.02
ng/ml). No proliferation activity was observed with the
negative control toxin rSEA.
MHC Class II Binding. To determine if there were sig-
nificant structural differences, the protein structures of
SMEZ-2, SPE-G, and SPE-H were modelled onto the su-
perimposed structurally conserved regions of SEA, SEB,
and SPE-C (Fig. 6). The models showed that in all three
proteins, the two amino acid side chains of the COOH-
terminal primary zinc binding motif are in close proximity
to a third potential zinc ligand to build a zinc binding site,
similar to the zinc binding site observed in SEA and SPE-C.
The zinc binding residues in SPE-C are H167, H201,
and D203, and it is thought that H81 from the HLA-DR1
b chain binds to the same zinc cation to form a regular tet-
rahedral complex. The two ligands of the primary zinc
binding motif, H201 and D203, are located on the b12
strand, which is part of the b-grasp motif, a common struc-
tural domain of SAgs. The third ligand, H167, comes from
the b10 strand (25).
In the model of SPE-G (Fig. 6 a, B) three potential zinc
binding ligands (H167, H202, and D204) are located at
corresponding positions. In the SMEZ-2 and the SPE-H
models (Fig. 6 a, A and C), the two corresponding b12 res-
idues are H202, D204 and H198, D200, respectively. The
third ligand in SPE-H (D160) and SMEZ-2 (H162) comes
from the b9 strand and is most similar to H187 in SEA. It
has been shown from crystal structures that H167 of SPE-C
and H187 of SEA are spatially and geometrically equivalent
sites (20, 25).
All SAgs examined so far, except SPE-C, bind to a con-
served motif in the MHC class II a1 domain. In SEB and
TSST, hydrophobic residues on the loop between the b1
and b2 strands project into a hydrophobic depression in the
MHC II a1 domain. This loop region has changed its
character in SPE-C, where the hydrophobic residues (F44,
L45, Y46, and F47 in SEB) are substituted by the less hy-
drophobic residues T33, T34, and H35. A comparison of
this region on the computer-generated models revealed
that the generic HLA-DR1 a chain binding site might also
be missing. As the loop regions are generated by random
choice, no conclusions can be made from their conforma-
tion in the models. However, in none of the three models
does the b1-b2 loop have the required hydrophobic fea-
tures observed in SEB and TSST (21, 24). The residues are
I25, D26, F27, K28, T279 and S30 in SMEZ-2; T31, T32,
N33, and S34 in SPE-G; and K28, N29, S30, P31, D32,
I33, V34, and T35 in SPE-H.
SMEZ-2 differs from SMEZ in only 17 amino acids. Fig.
6 b shows the computer-generated model of SMEZ-2 with
the position of those 17 residues. Most of the exchanges are
located on loop regions, most significantly on the b5-b6
loop with five consecutive residues replaced. The potential
zinc binding site and the b1-b2 loop are not affected by
the replaced amino acids.
The TCR Vb specificity differs between SMEZ and
SMEZ-2 by one Vb. SMEZ strongly stimulates Vb2 T
cells, but SMEZ-2 does not (Table II). One or more of the
17 exchanged residues in SMEZ/SMEZ-2 might therefore
be directly involved in TCR binding. The exact position
of the TCR binding site can not be predicted from the
model as several regions have been implicated in TCR
binding for different toxins. Crystal structures of SEC2 and
SEC3, complexed with a TCR-b chain, indicated the di-
rect role of several residues located on a2, the b2-b3 loop,
the b4-b5 loop, and a4 (41). On the other hand, binding
Table II. Vb Specificity of Recombinant Toxins on Human PBLs
Percentage of Vb enrichment
Vb Resting SMEZ SMEZ-2 SPE-G SPE-H
1.1 0.2 0.3 0.4 1.2 1
2.1 0.4 8.4 1 17.9 8.6
3.2 4.8 3.1 2.5 3 2.4
4.1 3.5 24.8 14.4 11.2 5.2
5.1 6.2 1.4 2.5 5.7 2.2
5.3 5.6 2.2 4.1 4.7 4.1
6.3 3 0.8 2.3 4.7 3.5
6.4 5.4 2.1 5.9 9.6 5.6
6.9 6.9 3.5 9.3 19.1 12.2
7.3 3.5 15.3 7.3 3.2 12.6
7.4 9 13.5 11.7 2.9 6.3
8.1 8.7 20.7 36 4.5 2.4
9.1 0.3 0.05 0 1.2 2.3
12.3 0.8 1.6 2 3.2 2.6
12.5 3 1.2 2 3 2.3
15.1 0.6 0.5 0.7 1.2 0.8
23.1 0.2 0.1 0.3 0.8 1
Total % 62.1 99.7 102.8 97.1 75.2
Human PBLs were incubated with 20 pg/ml of recombinant toxin for
4 d. Relative enrichment of Vb cDNAs was analyzed from RNA of
stimulated and resting PBLs by anchored primer PCR and reverse dot-
blot to a panel of 17 different Vb cDNAs (38). The figures represent
the percentage of each Vb with respect to total Cb.97 Proft et al.
of TSST to the TCR involves residues from a4, the b7-b8
loop, and the a4-b9 loop (24). The SMEZ-2 model shows
three residues, which might contribute to TCR binding. In
SMEZ, Lys is exchanged for Glu at position 80 and Thr is
exchanged for Ile at position 84, both on the b4-b5 loop.
On the COOH-terminal end of the a4 helix, Ala is re-
placed by Ser at position 143.
The results from the computer-modeled protein struc-
tures suggest that all four toxins, SMEZ, SMEZ-2, SPE-G,
and SPE-H, might bind to the HLA-DR1 b chain in a zinc
dependent fashion, similar to SEA and SPE-C, but might
not be able to interact with the HLA-DR1 a site, a situa-
tion that has previously only been observed with SPE-C
(25, 29).
To find out whether or not zinc is required for binding
of the toxins to MHC class II, a binding assay was per-
formed using human LG-2 cells (which are MHC class II–
expressing cells homozygous for HLA-DR1). Direct bind-
ing of 125I-labeled toxins was completely abolished in the
presence of 1 mM EDTA (Fig. 7, Table III). When 2 mM
ZnCl2 was added, binding to the LG-2 cells could be re-
stored completely. These results show that the toxins bind
in a zinc dependent mode, most likely to the HLA-DR1 b
chain similarly to SEA and SPE-C. However, it does yet
not exclude the possibility of an additional binding to the
HLA-DR1 a chain.
The biphasic binding of SEA to HLA-DR1 can be de-
duced from Scatchard analysis. It shows that SEA possesses
a high affinity binding site of 36 nM (which is the zinc de-
pendent b chain binding site) and a low affinity binding site
of 1 mM (a chain binding site). On the other hand, only
one binding site for HLA-DR1 was deduced from Scat-
chard analysis with SEB, TSST, and SPE-C, respectively
(Table III). Therefore, Scatchard analysis was performed
with radiolabeled rSMEZ, rSMEZ-2, rSPE-G, and rSPE-H
using LG-2 cells. All four toxins showed multiphasic curves
with at least two binding sites on LG-2 cells, a high affinity
site of 15–65 nM, and a low affinity site of 1–2 mM (Fig. 8,
Table III).
In a further attempt to determine the orientation of the
toxins on MHC class II, competition binding experiments
were performed. The recombinant toxins and reference
toxins (rSEA, rSEB, rSPE-C, and rTSST) were radiola-
Figure 7. Zinc dependent binding of SMEZ-2 to LG-2 cells. LG-2
cells were incubated in duplicates with 1 ng of 125I-labeled rSMEZ-2 and
increasing amounts of unlabeled toxin at 378C for 1 h, and then the cells
were washed and counted. s, incubation in media; m, incubation in me-
dia plus 1 mM EDTA; h, incubation in media plus 1 mM EDTA, 2 mM
ZnCl2.
Table III. Binding Affinities and Zinc Dependencies for SAgs to 
Human Class II
Toxin MHC class II binding kd [nM] zinc dependency
SEA 36/1,000 11
SEB 340 2
TSST 130 2
SPE-C 70 11
SMEZ 65/1,000 11
SMEZ-2 25/1,000 11
SPE-G 16/1,000 11
SPE-H 37/2,000 11
The binding affinities of the toxins to MHC class II were determined
by Scatchard analysis using LG-2 cells. Zinc dependency was deter-
mined by binding of recombinant toxins to LG-2 cells in the presence
and absence of EDTA, as described in the Materials and Methods sec-
tion.
Figure 8. Scatchard analysis of SMEZ-2 binding to LG-2 cells. 1 ng
125I-labeled rSMEZ-2 was incubated in duplicates with LG-2 cells and a
twofold dilution series of cold toxin (10 mg to 10 pg). After 1 h, cells
were washed and counted. Scatchard plots were performed as described
elsewhere (40). e, low affinity binding of SMEZ-2 to LG-2 cells; h,
high affinity binding of SMEZ-2 to LG-2 cells.98 Novel Streptococcal Superantigens
beled and tested with excess of unlabeled toxin for binding
to LG-2 cells. The results are summarized in Fig. 10. Both
rSEA and rSPE-C inhibited binding of labeled rSMEZ,
rSMEZ-2, rSPE-G, and rSPE-H. However, rSPE-C only
partially inhibited binding (50%) of the labeled rSMEZ-2
(Fig. 9). rSEB did not compete with any other toxin, even
at the highest concentration tested. rTSST was only slightly
competitive against 125I-labeled rSMEZ, rSMEZ-2 and
rSPE-G, respectively, and did not inhibit rSPE-H binding
at all.
Reciprocal competition experiments were performed.
rSMEZ, rSMEZ-2, and rSPE-H prevented 125I-rSEA from
binding to LG-2 cells. However, only partial competition
(50%) was observed even at the highest toxin concentra-
tions (10,000-fold molar excess). rSPE-G did not prevent
binding of 125I-rSEA, and 125I-rTSST binding was only
partially inhibited by rSMEZ, rSMEZ-2, and rSPE-H, but
not by rSPE-G. Significantly, none of the toxins inhibited
125I-rSEB binding, even at the highest concentration tested.
In a further set of competition binding experiments,
rSMEZ, rSMEZ-2, rSPE-G, and rSPE-H were tested for
competition against each other. Both rSMEZ and rSMEZ-2
competed equally with each other and also prevented bind-
ing of labeled rSPE-G and rSPE-H. In contrast, rSPE-G
and rSPE-H did not inhibit any other toxin binding, sug-
gesting that these toxins had the most restricted subset of
MHC class II molecules, which represent specific receptors.
Discussion
This paper reports the identification of four novel SAgs
from S. pyogenes: SPE-G, SPE-H, SPE-J, and SMEZ-2.
The spe-g, spe-h, and spe-j genes were found by screening
the S. pyogenes M1 genomic database at the University of
Oklahoma using short peptide sequences of highly con-
served regions. An attempt to clone smez from strain 2035
led to the identification of another novel sag gene (smez-2)
based on high sequence homology (95% DNA sequence
identity). These SAgs represent the only streptococcal
toxins thus far identified on the basis of their nucleotide
sequence and not by analysis of purified proteins.
SMEZ-2, SPE-G, and SPE-J are most similar to SPE-C
and the recently identified SMEZ (37). SPE-H is more
closely related to the staphylococcal SAgs than to any strep-
tococcal toxin. SMEZ-2 is the most potent SAg so far dis-
covered with a half-maximal response to stimulate T cells
approximately five times more active than that of SPE-C.
The function of these new SAgs provides an interesting
insight into the nature of SAg activation and the variation
that exists within this family of potent T cell mitogens. Per-
haps the most striking feature is the high frequency with
which Vb2 and Vb4 T cells are targeted. Out of the seven
SAgs examined thus far, five target Vb2 and three target
Vb4 as their principal T cell subgroup. The reason for this
remains an intriguing mystery but may suggest that there is
a specific role for Vb2-bearing T cells in streptococcal in-
duced immune defense. On the other hand, it might sim-
ply reflect the fact that the Vb2 domain has features more
amenable to ligation by this group of toxins. Only a careful
analysis of the Vb2–toxin interaction will resolve this issue.
The data represented in this paper suggest that SMEZ,
SMEZ-2, SPE-G, and SPE-H all bind to the MHC class II
b chain, but not to the a chain. Evidence that supports
binding exclusively to the b chain are as follows. (a) Pro-
tein structure models predict a putative zinc binding site
Figure 9. Competition binding study with SMEZ-2. LG-2 cells were
incubated in duplicates with 1 ng of 125I-labeled rSMEZ-2 and increasing
amounts of unlabeled rSMEZ-2, rSEA, rSEB, rTSST, or rSPE-C. After 1 h
cells were washed and counted. s, rSMEZ-2; m, rSEA; h, rSEB; o,
rTSST; r, rSPE-C. Figure 10. Summary of competitive binding experiments. Efficiency of
each labeled toxin to compete with a 10,000-fold molar excess of any
other unlabeled toxin for binding to LG-2 cells. White boxes, no compe-
tition; lightest gray boxes, 25% competition; medium gray boxes, 50%
competition; dark gray boxes, 75% competition; black boxes, 100% com-
petition. The results within the boxed area at the bottom right have been
published elsewhere (29).99 Proft et al.
similar to SEA and SPE-C, but suggest that the b1-b2 hy-
drophobic loop in SEA and SEB is significantly less hydro-
phobic in all four new streptococcal toxins. (b) All toxins
bind to LG-2 cells in a completely zinc dependent fashion.
(c) Scatchard analysis revealed a high affinity binding site
between 15 and 65 nM, similar to the HLA-DR1 b chain
affinities of SEA and SPE-C. (d) All toxins compete with
SEA and SPE-C for binding to HLA-DR1, but inhibit nei-
ther SEB nor TSST.
A putative zinc binding region was predicted for all four
toxins, comprising the COOH-terminal primary zinc bind-
ing motif (H-X-D) on the b12 strand and a third ligand
from the b9 strand (in SMEZ, SMEZ-2, and SPE-G) or
the b10 strand (in SPE-G). The role for zinc in binding to
MHC class II was confirmed by complete inhibition of cell
surface binding by 1 mM EDTA. Moreover, calculated
binding affinities were well in the range of the high affinity
binding determined for SEA and SPE-C to the MHC class
II b chain. Interestingly, the binding affinity for SPE-G (15
nM) is the highest so far determined for any toxin, yet
rSPE-G is a weaker stimulator of human T cells than SEA,
SPE-C, SMEZ, or SMEZ-2, indicating that affinity for
MHC class II does not equate with potency towards T
cells. A possible explanation is that although SPE-G binds
tightly to MHC class II, it might have a much lower affin-
ity for the TCR, or alternatively might assume an orienta-
tion on class II that is not optimal for TCR ligation. This
possibility might indicate that the orientation of a toxin
bound to MHC class II might be an important consider-
ation in how well TCRs are ligated and signals are trig-
gered.
Competitive binding studies provided evidence for the
exclusive binding to the MHC class II b chain. Neither
SEB nor TSST binding was inhibited by any of the new
toxins. The ability to partially compete with TSST might
best be explained by steric hindrance between the toxins
across the top of the MHC class II molecule, rather than by
direct competition for the a chain site. Exclusive MHC
class II b chain binding would therefore predict strong in-
hibition of SPE-C, but this was not the case. Only SMEZ
effectively inhibited SPE-C. The interpretation of this data
is that SPE-C targets a broader range of MHC class II mol-
ecules compared with any of the new toxins, whereas SPE-G,
which did not inhibit any other toxin, has a much more re-
stricted repertoire of MHC class II molecules. From these
data, a clear hierarchical order of binding can be shown:
(SPE-C, SMEZ) . SMEZ-2 . SPE-H . SPE-G. The
most likely explanation for the nature of these MHC class
II subsets is that they are defined by the bound antigenic
peptide. Indeed, peptide restriction has been reported for
several other SAgs (42). For example, SEB and TSST both
bind to the HLA-DR1 a chain, but do not cross-compete
at all, because peptides restrict their binding to different
HLA-DR1 subsets. Moreover, Thibodeau et al. (43) re-
ported that only a fraction of available MHC class II mole-
cules are actually able to bind a given SAg with high affin-
ity. This might also explain the multiphasic Scatchard plots
of SMEZ, SMEZ-2, SPE-G, and SPE-H binding when
toxins have a variety of affinities ranging from nanomolar
to micromolar defined by different peptides. Other possible
explanations might be (a) binding of the toxins to a second,
as yet undetermined class II site; (b) binding to different
class II isotypes; and (c) binding to a non–class II receptor.
Another interesting finding is the complete lack of pro-
liferation response when SPE-G and SPE-C were tested on
murine T cells, although it has been shown that SPE-C
binds to murine MHC class II (I-E) (29). Two possible
mechanisms can be evoked to explain this feature. One
possibility is that there is no equivalent to human Vb2
TCR in mice. This seems unlikely, as all other Vb2 spe-
cific toxins are potent stimulators of mouse T cells. The
second possibility is that the orientation of SPE-C and
SPE-G on mouse class II does not allow ligation of murine
TCR molecules.
Both SMEZ and SMEZ-2 specifically stimulated human
Vb8 T cells. A Vb8-specific activity had previously been
detected in contaminated preparations of SPE-A and SPE-B
and in crude extracts of certain S. pyogenes strains. The
agent responsible for this specific activity remained elusive,
but was believed to be another SAg, named SPE-X (35).
SMEZ and SMEZ-2 are both potent stimulators of Vb8
and thus are good candidates for the elusive SPE-X. Inter-
estingly, Abe et al. (44) reported a selective expansion of T
cells expressing Vb2 and Vb8 from patients with Kawasaki
disease (KD), an acute multisystem vasculitis of young chil-
dren most prevalent in Japan (45). Epidemiologic evidence
strongly supports an infectious etiology for this disease. The
causative agent for KD is unknown, but SAgs have been
implicated in triggering the disease (44, 46). The Vb2 and
Vb8 specificity of SMEZ correlates well with the selective
T cell expansion in KD patients reported by Abe and co-
workers (44). Further studies are underway to examine the
frequency of these new SAgs and whether expression can
be related to diseases such as KD.
The identification of the novel toxins increases the total
number of known SAgs to eight and the confirmed bacte-
rial SAg family to nineteen. However, individual strepto-
coccal strains seem to carry only a limited number of SAg
genes. A recent study by Cockerill et al. (47) examined the
frequency of toxin genes in strains isolated from patients
with invasive streptococcal disease. Only one strain carried
three different toxins genes, spe-a, spe-c, and ssa. In this
study, we show that strain 2035 lacks the smez and spe-h
genes, whereas the M1 strain lacks the smez-2 gene. Vari-
able sag gene frequencies among different strains is most
likely due to horizontal gene transfer by mobile genetic el-
ements such as phage or insertion element (12, 48). It is
clear from this limited analysis of the four new sag genes
that they too are subject to variable existence throughout
the S. pyogenes strains. A larger screening of clinical isolates
for these new sag genes is currently underway to determine
which are the most common SAgs.
By expanding the family of SAgs, much stronger predic-
tions about the general mechanism of SAg activation can
be made. Despite the variation of SAgs, it appears that there
is a significant preference for binding of certain Vbs, such100 Novel Streptococcal Superantigens
as Vb2 and Vb4 and for exclusive binding of the MHC
class II b chain. However, the actual binding to class II ap-
pears to be more complex and variable, with a clear hierar-
chy of binding, most likely due to peptide restriction. This
complex binding pattern to MHC class II might in fact be
very finely tuned and might have an impact on the fate of
SAg-activated T cells in terms of apoptosis, anergy, and the
development of autoimmune diseases. It may also represent
the difference between host susceptibility and resistance to
streptococcus mediated disease. 
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